Castleman Disease Trial, Recruiting NCT00006518 Sponsor: National Cancer Institute (NCI) Condition: Castleman Disease
Back to Castleman Disease

Castleman Disease Trial, Recruiting

NCT00006518
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You must be 18 years old or older.
  • You must be well enough to carry out some daily activities — your overall health level is measured on a standard scale, and you need to meet a minimum threshold (confirm with trial site).
  • You must meet at least one of the following conditions: you have been exposed to HIV, KSHV, or HPV; you have tested positive for HIV; you have tested positive for KSHV (a herpes virus linked to certain cancers); you have tested positive for EBV (the virus that causes mono); or you have tested positive for HTLV-1 (a virus that can affect the immune system).
  • If you have previously tested positive for any of these viruses, or have had a related condition such as Kaposi's sarcoma, a type of lymphoma called primary effusion lymphoma, or a condition called Multicentric Castleman's disease, this also counts toward eligibility.
  • You have a cancer, Multicentric Castleman's disease, or skin lesions that look like they could be Kaposi's sarcoma.
  • You have abnormal cell changes in the cervix or the anal area (precancerous lesions).
  • You are able to understand the study information and are willing to sign a consent form agreeing to take part.

Who may not be able to join:

  • There are no specific exclusion criteria listed for this trial.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Robert Yarchoan, M.D., National Cancer Institute (NCI)

Phone: (240) 760-6074

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Registry
ClinicalTrials.gov
Start date
6 December 2000

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Acquisition of serum, circulating cells, bone marrow, and tumor or normal tissue samples from participants with HIV infection, KSHV infection, or with cancer.

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov